Utility and Diversity: Challenges for Genomic Medicine

Literature Cited

1. 1. 

   Adams P, Barton JC, McLaren GD, Acton RT, Speechley M et al. 2009. Screening for iron overload: lessons from the HEmochromatosis and IRon Overload Screening (HEIRS) study. Can. J. Gastroenterol. 23:769–72
   [Google Scholar]
2. 2. 

   Appelbaum PS, Parens E, Berger SM, Chung WK, Burke W. 2019. Is there a duty to reinterpret genetic data? The ethical dimensions. Genet. Med. 22:633–39
   [Google Scholar]
3. 3. 

   Aronowitz R. 2015. Risky Medicine Chicago: Univ. Chicago Press
4. 4. 

   Aslibekyan S, Vaughan LK, Wiener HW, Hidalgo BA, Lemas DJ et al. 2016. Linkage and association analysis of circulating vitamin D and parathyroid hormone identifies novel loci in Alaska Native Yup'ik people. Genes Nutr 11:23
   [Google Scholar]
5. 5. 

   Atkins D, Siegel J, Slutsky J. 2005. Making policy when the evidence is in dispute. Health Aff 24:102–13
   [Google Scholar]
6. 6. 

   Atkins JL, Pilling LC, Masoli JAH, Kuo CL, Shearman JD et al. 2020. Association of hemochromatosis HFE p.c282y homozygosity with hepatic malignancy. JAMA 324:2048–57
   [Google Scholar]
7. 7. 

   Au N, Gil MR, Boyer B, Hopkins S, Black J et al. 2017. Dietary and genetic influences on hemostasis in a Yup'ik Alaska Native population. PLOS ONE 12:e0173616
   [Google Scholar]
8. 8. 

   Baker JL, Rotimi CN, Shriner D. 2017. Human ancestry correlates with language and reveals that race is not an objective genomic classifier. Sci. Rep. 7:1572
   [Google Scholar]
9. 9. 

   Bergman AB, Stamm SJ. 1966. The morbidity of cardiac non-disease in school children. N. Engl. J. Med. 276:1008–13
   [Google Scholar]
10. 10. 

    Beskow LM, Hammack-Aviran CM, Brelsford KM. 2020. Thought leader comparisons of risks in precision medicine research. Ethics Hum. Res. 42:35–40
    [Google Scholar]
11. 11. 

    Bommersbasch J. 2008. Arizona's broken arrow: Did Arizona State University genetically rape the Havasupai Tribe?. Phoenix Magazine Nov., pp 134–44 https://janabommersbach.com/arizonas-broken-arrow-did-arizona-state-university-genetically-rape-the-havasupai-tribe
    [Google Scholar]
12. 12. 

    Bowen DJ, Battuello KM, Raats M. 2005. Marketing genetic tests: empowerment or snake oil?. Health Educ. Behav. 32:676–85
    [Google Scholar]
13. 13. 

    Bowen DJ, Burke W, Yasui Y, McTiernan A, McLeran D. 2002. Effects of risk counseling on interest in breast cancer testing for lower risk women. Genet. Med. 4:359–65
    [Google Scholar]
14. 14. 

    Bowen DT, McTiernan A, Burke W, Powers D, Pruski J et al. 1999. Participation in breast cancer risk counseling among women with a family history. Cancer Epidemiol. Biomark. Prev. 8:581–85
    [Google Scholar]
15. 15. 

    Boyer BB, Dillard D, Woodahl EL, Whitener R, Thummel KE, Burke W. 2011. Ethical issues in developing pharmacogenetic research partnerships with American Indigenous communities. Clin. Pharmacol. Ther. 89:343–45
    [Google Scholar]
16. 16. 

    Braveman P, Egerter S, Williams DR. 2011. The social determinants of health: coming of age. Annu. Rev. Public Health 32:381–98
    [Google Scholar]
17. 17. 

    Burke W, Acheson L, Botkin J, Bridges K, Davis A et al. 2002. Genetics in primary care: a USA faculty development initiative. Commun. Genet. 5:138–46
    [Google Scholar]
18. 18. 

    Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J et al. 2002. Genetic test evaluation: information needs of clinicians, policy-makers and the public. Am. J. Epidemiol. 156:311–18
    [Google Scholar]
19. 19. 

    Burke W, Burton H, Hall AE, Karmali M, Khoury MJ et al. 2010. Extending the reach of public health genomics: What should be the agenda for public health in an era of genome-based and “personalized” medicine?. Genet. Med. 12:785–91
    [Google Scholar]
20. 20. 

    Burke W, Clayton EW, Wolf SM, Berry SA, Evans BJ et al. 2019. Improving recommendations for genomic medicine: building an evolutionary process from clinical practice advisory documents to guidelines. Genet. Med. 21:2431–38
    [Google Scholar]
21. 21. 

    Burke W, Culver J, Pinsky L, Hall S, Reynolds S et al. 2009. Genetic assessment of breast cancer risk in primary care practice. Am. J. Med. Genet. A 149A:349–45
    [Google Scholar]
22. 22. 

    Burke W, Culver JB, Bowen D, Lowry D, Durfy S et al. 2000. Genetic counseling for women with an intermediate family history of breast cancer. Am. J. Med. Genet. 90:361–68
    [Google Scholar]
23. 23. 

    Burke W, Daly M, Garber JE, Botkin J, Kahn MJE et al. 1997. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 2. BRCA1 and BRCA2. JAMA 277:997–1003
    [Google Scholar]
24. 24. 

    Burke W, Fangman WL. 1975. Temporal order in yeast chromosome replication. Cell 5:263–69
    [Google Scholar]
25. 25. 

    Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ. 2000. Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genet. Med. 2:271–77
    [Google Scholar]
26. 26. 

    Burke W, Kroese M, Zimmern R. 2007. Defining purpose: a key step in genetic test evaluation. Genet. Med. 9:675–81
    [Google Scholar]
27. 27. 

    Burke W, Laberge A-M, Press N. 2010. Debating clinical utility. Public Health Genom 13:215–23
    [Google Scholar]
28. 28. 

    Burke W, Matheny Antommaria AH, Bennett R, Botkin J, Clayton EW et al. 2013. Recommendations for returning genomic incidental findings? We need to talk. ! Genet. Med. 15:854–59
    [Google Scholar]
29. 29. 

    Burke W, Petersen G, Lynch P, Daly M, Garber JE et al. 1997. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 1. Hereditary nonpolyposis colon cancer. JAMA 277:915–19
    [Google Scholar]
30. 30. 

    Burke W, Pinsky L, Press N. 2001. Categorizing genetic tests to identify their ethical, legal and social implications. Am. J. Med. Genet. C 106:233–40
    [Google Scholar]
31. 31. 

    Burke W, Psaty BM. 2007. Personalized medicine in the era of genomics. JAMA 298:1682–84
    [Google Scholar]
32. 32. 

    Burke W, Tarini B, Press N, Evans JP. 2011. Genetic screening. Epidemiol. Rev. 33:148–64
    [Google Scholar]
33. 33. 

    Burke W, Thomson E, Khoury MJ, McDonnell SM, Press N et al. 1998. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 280:172–78
    [Google Scholar]
34. 34. 

    Burke W, Trinidad SB, Schenck D. 2019. Can precision medicine reduce the burden of diabetes?. Ethn. Dis 29:Suppl. 3669–74
    [Google Scholar]
35. 35. 

    Cent. Dis. Control Prev 2020. Public Health Genomics and Precision Health Knowledge Base (v6.8): Tier-Classified Guidelines Database Accessed Nov. 16, 2020. https://phgkb.cdc.gov/PHGKB/tierStartPage.action
36. 36. 

    Chapman-Davis E, Zhou ZN, Fields JC, Frey MK, Jordan B et al. 2021. Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center. J. Gen. Intern. Med. 36:35–42
    [Google Scholar]
37. 37. 

    Claw KG, Anderson MZ, Begay RL, Tsosie KS, Fox K, Garrison NA. 2018. A framework for enhancing ethical genomic research with Indigenous communities. Nat. Commun. 9:2957
    [Google Scholar]
38. 38. 

    Claw KG, Beans JA, Lee SB, Avey JP, Stapleton PA et al. 2020. Pharmacogenomics of nicotine metabolism: novel CYP2A6 and CYP2B6 genetic variation patterns in Alaska Native and American Indian populations. Nicotine Tob. Res. 22:910–18
    [Google Scholar]
39. 39. 

    Collins FS. 1999. Shattuck Lecture: medical and societal consequences of the Human Genome Project. N. Engl. J. Med. 341:28–37
    [Google Scholar]
40. 40. 

    Crosslin DR, Carrell DS, Burt A, Kim DS, Underwood JG et al. 2015. Genetic variation in the HLA region is associated with susceptibility to herpes zoster. Genes Immun 16:1–7
    [Google Scholar]
41. 41. 

    Curtis JR, Burke W, Kassner AW, Aitken ML. 1997. Absence of health insurance is associated with decreased life expectancy in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 155:1921–24
    [Google Scholar]
42. 42. 

    Danaei G, Rimm EB, Oza S, Kulkarni SC, Murray CJL, Ezzati M. 2010. The promise of prevention: the effects of four preventable risk factors on national life expectancy and life expectancy disparities by race and county in the United States. PLOS Med 7:e1000248
    [Google Scholar]
43. 43. 

    Deugnier Y, Morcet J, Lainé F, Hamdi-Roze H, Bollard AS et al. 2019. Reduced phenotypic expression in genetic hemochromatosis with time: role of exposure to non-genetic modifiers. J. Hepatol. 70:118–25
    [Google Scholar]
44. 44. 

    Dorfman EH, Brown Trinidad S, Morales CT, Howlett K, Burke W, Woodahl EL. 2015. Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas. Pharmacogenomics 16:227–37
    [Google Scholar]
45. 45. 

    Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U et al. 2014. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol. 55:89–106
    [Google Scholar]
46. 46. 

    Durfy S, Bowen D, McTiernan A, Sporleder J, Burke W. 1999. Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of western Washington state women. Cancer Epidemiol. Biomark. Prev. 8:369–75
    [Google Scholar]
47. 47. 

    Eisenberg J. 1999. Ten lessons for evidence-based technology assessment. JAMA 282:1865–69
    [Google Scholar]
48. 48. 

    Eisinger F, Geller G, Burke W, Holtzman NA. 1999. Cultural basis for differences between American and French clinical recommendations for women at increased risk of breast/ovarian cancer. Lancet 353:919–20
    [Google Scholar]
49. 49. 

    Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA et al. 1996. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13:399–408
    [Google Scholar]
50. 50. 

    Fohner AE, Muzquiz LI, Austin MA, Gaedigk A, Gordon A et al. 2013. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet. Genom. 23:403–14
    [Google Scholar]
51. 51. 

    Fohner AE, Robinson R, Yracheta J, Dillard DA, Schilling B et al. 2015. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenet. Genom. 25:343–53
    [Google Scholar]
52. 52. 

    Fohner AE, Wang Z, Yracheta J, O'Brien DM, Hopkins SE et al. 2016. Genetics, diet, and season are associated with serum 25-hydroxycholecalciferol concentration in a Yup'ik study population from southwestern Alaska. J. Nutr. 146:318–25
    [Google Scholar]
53. 53. 

    Fraiman YS, Wojcik MH. 2021. The influence of social determinants of health on the genetic diagnostic odyssey: Who remains undiagnosed, why, and to what effect?. Pediatr. Res. 89:295–300
    [Google Scholar]
54. 54. 

    Frieden TR. 2010. A framework for public health action: the health impact pyramid. Am. J. Public Health 100:590–95
    [Google Scholar]
55. 55. 

    Gaffney A, McCormick D. 2017. The Affordable Care Act: implications for health-care equity. Lancet 389:1442–52
    [Google Scholar]
56. 56. 

    Gan EK, Powell LW, Olynyk JK. 2011. Natural history and management of HFE-hemochromatosis. Semin. Liver Dis. 31:293–301
    [Google Scholar]
57. 57. 

    Garrison NA, Barton KS, Porter KM, Mai Y, Burke W, Carroll SR 2019. Access and management: Indigenous perspectives on genomic data sharing. Ethn. Dis. 29:Suppl. 3659–68
    [Google Scholar]
58. 58. 

    Garrison NA, Cho MK. 2013. Awareness and acceptable practices: IRB and researcher reflections on the Havasupai lawsuit. AJOB Prim. Res. 4:55–63
    [Google Scholar]
59. 59. 

    Garrison NA, Hudson M, Ballantyne LL, Garba I, Martinez A et al. 2019. Genomic research through an Indigenous lens: understanding the expectations. Annu. Rev. Genom. Hum. Genet. 20:495–517
    [Google Scholar]
60. 60. 

    Ginsburg GS, Wu RR, Orlando LA. 2019. Family health history: underused for actionable risk assessment. Lancet 394:596–603
    [Google Scholar]
61. 61. 

    Goldstein JL, Brown MS. 2009. History of discovery. Arterioscl. Thromb. Vasc. Biol. 29:431–38
    [Google Scholar]
62. 62. 

    Green RC, Berg JS, Grody WW, Kalia SS, Korf BR et al. 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15:565–74
    [Google Scholar]
63. 63. 

    Greenberg S, Yashar BM, Pearlman M, Duquette D, Milliron K, Marvin M. 2019. Evaluating and improving the implementation of a community-based hereditary cancer screening program. J. Community Genet. 10:51–60
    [Google Scholar]
64. 64. 

    Guyatt G, Cairns J, Churchill D, Cook D, Haynes B et al. 1992. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 268:2420–25
    [Google Scholar]
65. 65. 

    Hallford HG, Coffman MA, Obregon-Tito AJ, Morales AH, Williamson DL. 2020. Access barriers to genetic services for Spanish-speaking families in states with rapidly growing migrant populations. J. Genet. Couns. 29:365–80
    [Google Scholar]
66. 66. 

    Henderson LM, Robinson RF, Ray L, Khan BA, Li T et al. 2019. VKORC1 and novel CYP2C9 variation predict warfarin response in Alaska Native and American Indian people. Clin. Transl. Sci. 12:312–20
    [Google Scholar]
67. 67. 

    Hindorff LA, Bonham VL, Brody LC, Ginoza MEC, Hutter CM et al. 2017. Prioritizing diversity in human genomics research. Nat. Rev. Genet. 19:175–85
    [Google Scholar]
68. 68. 

    Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S et al. 2016. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ 352:i1102
    [Google Scholar]
69. 69. 

    Hoskins KF, Tejeda S, Vijayasiri G, Chukwudozie IB, Remo MH et al. 2018. A feasibility study of breast cancer genetic risk assessment in a federally qualified health center. Cancer 124:3733–41
    [Google Scholar]
70. 70. 

    Hover AR, McDonnell SM, Burke W. 2004. Changing the clinical management of hereditary hemochromatosis: translating screening and early case detection strategies into clinical practice. Arch. Intern. Med. 164:957–61
    [Google Scholar]
71. 71. 

    Ifill S, Lynch L, Stevenson B, Thompson AC. 2018. A Perilous Path: Talking Race, Inequality, and the Law New York: New Press
72. 72. 

    Indian Health Serv 2016. Tribal self-governance. Indian Health Service https://www.ihs.gov/newsroom/index.cfm/factsheets/tribalselfgovernance
    [Google Scholar]
73. 73. 

    Inst. Med 2003. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care Washington, DC: Natl. Acad. Press
74. 74. 

    Ioannidis JPA, Khoury MJ. 2018. Evidence-based medicine and big genomic data. Hum. Mol. Genet. 27:R2–7
    [Google Scholar]
75. 75. 

    Israel B, Schultz AJ, Parker EA, Becker AB. 1998. Review of community based research: assessing partnership approaches to improve public health. Annu. Rev. Public Health 19:173–202
    [Google Scholar]
76. 76. 

    Jaja C, Burke W, Thummel K, Edwards K, Veenstra DL. 2008. Cytochrome p450 enzyme polymorphism frequency in Indigenous and Native American populations: a systematic review. Community Genet 11:141–49
    [Google Scholar]
77. 77. 

    James RD, Gold DE, St John-BlackBird A, Brown Trinidad S 2015. Factors that influence mammography use among older American Indian and Alaska Native women. J. Transcult. Nurs. 26:137–45
    [Google Scholar]
78. 78. 

    James RD, Starks H, Segrest VA, Burke W. 2012. From leaky pipeline to irrigation system: minority education through the lens of community-based participatory research. Prog. Community Health Partnersh. 6:471–79
    [Google Scholar]
79. 79. 

    James RD, Tsosie R, Sahota P, Parker M, Dillard D et al. 2014. Exploring pathways to trust: a tribal perspective on data sharing. Genet. Med. 16:820–26
    [Google Scholar]
80. 80. 

    James RD, West KM, Claw KG, EchoHawk A, Dodge L et al. 2018. Responsible research with urban American Indians and Alaska Natives. Am. J. Public Health 108:1613–16
    [Google Scholar]
81. 81. 

    Jonsen AR, Durfy SJ, Burke W, Motulsky AG. 1996. The advent of the ‘unpatients.’. Nat. Med. 2:622–24
    [Google Scholar]
82. 82. 

    Jooma S, Hahn MJ, Hindorff LA, Bonham VL. 2019. Defining and achieving health equity in genomic medicine. Ethn. Dis. 29:Suppl. 1173–78
    [Google Scholar]
83. 83. 

    Kahneman D. 2011. Thinking Fast and Slow New York: Farrar, Straus & Giroux
84. 84. 

    Kelley M, Edwards K, Starks H, Fullerton SM, James R et al. 2012. Values in translation: how asking the right questions can move translational science toward greater health impact. Clin. Transl. Sci. 5:445–51
    [Google Scholar]
85. 85. 

    Khan BA, Robinson R, Fohner AE, Muzquiz LI, Schilling BD et al. 2018. Cytochrome P450 genetic variation associated with tamoxifen biotransformation in American Indian and Alaska Native people. Clin. Transl. Sci. 11:312–21
    [Google Scholar]
86. 86. 

    Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C et al. 2018. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50:1219–24
    [Google Scholar]
87. 87. 

    Khoury MJ, Feero WG, Chambers DA, Brody LC, Aziz N et al. 2018. A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health. PLOS Med 15:e1002631
    [Google Scholar]
88. 88. 

    King MC, Levy-Lahad E, Lahad A. 2014. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 312:1091–2
    [Google Scholar]
89. 89. 

    Korngiebel DM, Thummel KE, Burke W. 2017. Implementing precision medicine: the ethical challenges. Trends Pharmacol. Sci. 38:8–14
    [Google Scholar]
90. 90. 

    Krieger N, Chen JT, Waterman PD. 2010. Decline in US breast cancer rates after the Women's Health Initiative: socioeconomic and racial/ethnic differentials. Am. J. Public Health 100:Suppl. 1S132–39
    [Google Scholar]
91. 91. 

    Landry LG, Ali N, Williams DR, Rehm HL, Bonham VL. 2018. Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice. Health Aff 37:780–85
    [Google Scholar]
92. 92. 

    Landry LG, Rehm HL. 2018. Association of racial/ethnic categories with the ability of genetic tests to detect a cause of cardiomyopathy. JAMA Cardiol 3:341–45
    [Google Scholar]
93. 93. 

    Lark ME, Kirkpatrick K, Hung KC. 2018. Patient safety movement: history and future directions. J. Hand Surg. Am. 43:174–78
    [Google Scholar]
94. 94. 

    Lucaroni F, Cicciarella Modica D, Macino M, Palombi L, Abbondanzieri A et al. 2019. Can risk be predicted? An umbrella systematic review of current risk prediction models for cardiovascular diseases, diabetes and hypertension. BMJ Open 9:e030234
    [Google Scholar]
95. 95. 

    Manolio TA, Bult CA, Chisolm RL, Deverka PA, Ginsburg GA et al. 2019. Genomic medicine year in review: 2019. Am. J. Hum. Genet. 105:1072–75
    [Google Scholar]
96. 96. 

    Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE et al. 2013. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310:1353–68
    [Google Scholar]
97. 97. 

    Manson SM, Garroutte E, Goins RT, Henderson PN. 2004. Access, relevance, and control in the research process: lessons from Indian country. J. Aging Health 16:5 Suppl58S–77S
    [Google Scholar]
98. 98. 

    Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. 2019. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 51:584–91
    [Google Scholar]
99. 99. 

    McClean RM. 2019. Are internists team leaders or orchestra conductors?. ACP Internist Nov./Dec. https://acpinternist.org/archives/2019/11/are-internists-team-leaders-or-orchestra-conductors.htm
    [Google Scholar]
100. 100. 

     McDonald MG, Henderson LM, Ray S, Yeung CK, Johnson AL et al. 2020. Heterologous expression and functional characterization of novel CYP2C9 variants identified in the Alaska Native people. J. Pharmacol. Exp. Ther. 374:233–40
     [Google Scholar]
101. 101. 

     McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ et al. 1999. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am. J. Med. 106:619–24
     [Google Scholar]
102. 102. 

     Mersch J, Brown N, Pirzadeh-Miller S, Mundt E, Cox HC et al. 2018. Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA 320:1266–74
     [Google Scholar]
103. 103. 

     Morales CT, Muzquiz LI, Howlett K, Azure B, Bodnar B et al. 2016. Partnership with the Confederated Salish and Kootenai tribes: establishing an advisory committee for pharmacogenetic research. Prog. Community Health Partnersh. 10:173–83
     [Google Scholar]
104. 104. 

     Natl. Acad. Sci Eng. Med 2017. An Evidence Framework for Genetic Testing Washington DC: Natl. Acad. Press
105. 105. 

     Natl. Cancer Inst 2020. Genetics of breast and gynecologic cancers (PDQ®) – health professional version. National Cancer Institute https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq
     [Google Scholar]
106. 106. 

     Natl. Congr. Am. Indians 2018. Healthcare: reducing disparities in the federal health care budget Rep. Natl. Congr. Am. Indians Washington, DC: https://www.ncai.org/06_health_care.pdf
107. 107. 

     Natl. Hum. Genome Res. Inst 2020. Ethical, Legal and Social Implications Research Program. National Human Genome Research Institute https://www.genome.gov/Funded-Programs-Projects/ELSI-Research-Program-ethical-legal-social-implications
     [Google Scholar]
108. 108. 

     Natl. Res. Counc. Comm. Eval. 1950s Air Force Hum. Test. Alsk. Using Radioact. Iodine 131 1996. The Arctic Aeromedical Laboratory's Thyroid Function Study: A Radiological Risk and Ethical Analysis Washington, DC: Natl. Acad. Press https://www.ncbi.nlm.nih.gov/books/NBK232532
109. 109. 

     Oliver JE. 2006. Fat Politics New York: Oxford Univ. Press
110. 110. 

     Orlando LA, Wu RR, Beadles C, Himmel T, Buchanan AH et al. 2014. Implementing family health history risk stratification in primary care: impact of guideline criteria on populations and resource demand. Am. J. Med. Genet. C 166C:24–33
     [Google Scholar]
111. 111. 

     Peterson JF, Roden DM, Orlando LA, Ramirez AH, Mensah GA, Williams MS. 2019. Building evidence and measuring clinical outcomes for genomic medicine. Lancet 394:604–10
     [Google Scholar]
112. 112. 

     Phatak PD, Bonkovsky HL, Kowdley KV. 2008. Hereditary hemochromatosis: time for targeted screening. Ann. Intern. Med. 149:270–72
     [Google Scholar]
113. 113. 

     Phelan JC, Link BG, Tehranifar P. 2010. Social conditions as fundamental causes of health inequalities: theory, evidence, and policy implications. J. Health Soc. Behav. 51:Suppl.S28–40
     [Google Scholar]
114. 114. 

     Pilling LC, Tamosauskaite J, Jones G, Wood AR, Jones L et al. 2019. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ 364:k5222
     [Google Scholar]
115. 115. 

     Popejoy AB, Fullerton SM. 2016. Genomics is failing on diversity. Nature 538:161–64
     [Google Scholar]
116. 116. 

     Press NA, Reynolds S, Pinsky L, Murthy V, Leo M, Burke W 2005. ‘That's like chopping off a finger because you're afraid it might get broken’: disease and illness in women's views of prophylactic mastectomy. Soc. Sci. Med. 61:1106–17
     [Google Scholar]
117. 117. 

     Press NA, Yasui Y, Reynolds S, Durfy SJ, Burke W. 2001. Women's interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations. Am. J. Med. Genet. 99:99–110
     [Google Scholar]
118. 118. 

     Rich EC, Burke W, Heaton CJ, Haga S, Pinsky L et al. 2004. Reconsidering the family history in primary care. J. Gen. Intern. Med. 19:273–80
     [Google Scholar]
119. 119. 

     Roberts ME, Susswein LR, Cheng WJ, Carter NJ, Carter AC et al. 2020. Ancestry-specific hereditary cancer panel yields: moving toward more personalized risk assessment. J. Genet. Couns 29:598–606
     [Google Scholar]
120. 120. 

     Roden DM, McLeod HL, Relling MV, Williams MS, Menash GA et al. 2019. Pharmacogenomics. Lancet 394:521–32
     [Google Scholar]
121. 121. 

     Roth JA, Garrison LP, Burke W, Ramsey SD, Veenstra DL. 2011. Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genom 14:59–67
     [Google Scholar]
122. 122. 

     Sarkar U, Lopez A, Maselli JH, Gonzales R 2011. Adverse drug events in US adult ambulatory medical care. Health Serv. Res. 46:1517–33
     [Google Scholar]
123. 123. 

     Schully SD, Lam TK, Dotson WD, Chang CQ, Aronson N et al. 2015. Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genet. Med. 17:63–67
     [Google Scholar]
124. 124. 

     Shaw JL, Robinson R, Starks H, Burke W, Dillard DA. 2013. Risk, reward and the double-edged sword: perspectives on pharmacogenetic research and clinical testing among Alaska Native people. Am. J. Public Health 103:2220–25
     [Google Scholar]
125. 125. 

     Shendre A, Dillon C, Limdi NA. 2018. Pharmacogenetics of warfarin dosing in patients of African and European ancestry. Pharmacogenomics 19:1357–71
     [Google Scholar]
126. 126. 

     Shields AE, Burke W, Levy DE. 2008. The use of available genetic tests among minority-serving physicians in the US. Genet. Med. 10:404–14
     [Google Scholar]
127. 127. 

     Shirts BH, Pritchard CC, Walsh T. 2016. Family-specific variants and the limits of human genetics. Trends Mol. Med. 22:925–34
     [Google Scholar]
128. 128. 

     Simonds VW, Goins RT, Krantz EM, Garroutte EM. 2014. Cultural identity and patient trust among older American Indians. J. Gen. Intern. Med. 29:500–6
     [Google Scholar]
129. 129. 

     Stent G. 1969. The Coming of the Golden Age Garden City, NY: Nat. Hist. Press
130. 130. 

     Tanner JA, Zhu AZ, Claw KG, Prasad B, Korchina V et al. 2018. Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. Pharmacogenet. Genom. 28:7–16
     [Google Scholar]
131. 131. 

     Tonelli MR, Curtis JR, Guntupalli KK, Rubenfeld GD, Arroliga AC et al. 2012. An official multi-society statement: the role of clinical research results in the practice of critical care medicine. Am. J. Respir. Crit. Care Med. 185:1117–24
     [Google Scholar]
132. 132. 

     Tonelli MR, Shapiro D. 2020. Experiential knowledge in clinical medicine: use and justification. Theor. Med. Bioeth. 41:67–82
     [Google Scholar]
133. 133. 

     Trinidad SB, Fullerton SM, Ludman EJ, Jarvik GP, Larson EB, Burke W. 2011. Research practice and participant preferences: the growing gulf. Science 331:287–88
     [Google Scholar]
134. 134. 

     Trinidad SB, Ludman EJ, Hopkins S, James RD, Hoeft TJ et al. 2015. Community dissemination and genetic research: moving beyond results reporting. Am. J. Med. Genet. A 167:1542–50
     [Google Scholar]
135. 135. 

     Veenstra DL, Roth JA, Garrison LP Jr., Ramsey SD, Burke W. 2010. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet. Med. 12:686–93
     [Google Scholar]
136. 136. 

     Welch HG, Burke W. 1998. Uncertainties in genetic testing for chronic disease. JAMA 280:1525–27
     [Google Scholar]
137. 137. 

     West KM, Blacksher E, Burke W. 2017. Genomics, health disparities, and missed opportunities for the nation's research agenda. JAMA 317:1831–32
     [Google Scholar]
138. 138. 

     Williams MS. 2019. Early lessons from the implementation of genomic medicine programs. Annu. Rev. Genom. Hum. Genet. 20:389–411
     [Google Scholar]
139. 139. 

     Wilson J. 1998. The Earth Shall Weep New York: Atl. Mon. Press
140. 140. 

     Woodahl EL, Lesko LJ, Hopkins S, Robinson RF, Thummel KE, Burke W. 2014. Pharmacogenetic research in partnership with American Indian and Alaska Native communities. Pharmacogenomics 15:1235–41
     [Google Scholar]
141. 141. 

     Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M et al. 2002. Screening of infants and mortality due to neuroblastoma. N. Engl. J. Med. 346:1041–46
     [Google Scholar]
142. 142. 

     Woolf SH, Harris R. 2012. The harms of screening: new attention to an old concern. JAMA 307:565–66
     [Google Scholar]
143. 143. 

     Wu RR, Myers RA, Sperber N, Voils CI, Neuner J et al. 2019. Implementation, adoption and utility of family health history risk assessment in diverse care settings: evaluation implementation processes and impact with an implementation framework. Genet. Med. 21:331–38
     [Google Scholar]
144. 144. 

     Yarnall KS, Pollak KI, Østbye T, Krause KM, Michener JL. 2003. Primary care: Is there enough time for prevention?. Am. J. Public Health 93:635–41
     [Google Scholar]
145. 145. 

     Young BA, Blacksher E, Cavanaugh KL, Freedman BI, Fullerton SM et al. 2019. Apolipoprotein L1 testing in African Americans: involving the community in policy discussions. Am. J. Nephrol. 50:303–11
     [Google Scholar]